BioView develops, manufactures and markets automated cell imaging and analysis systems for cytology, cytogenetics, pathology and research laboratories worldwide. Its platforms combine motorized microscopy with AI-assisted imaging, analysis and review for workflows such as FISH and karyotyping, and are used by more than 800 laboratories. The company has operated since 2000, is headquartered in Israel with a fully owned US subsidiary, and is publicly traded on the Tel Aviv Stock Exchange under the symbol BIOV.